PMID- 31331582 OWN - NLM STAT- MEDLINE DCOM- 20200109 LR - 20200109 IS - 1873-6963 (Electronic) IS - 0965-2299 (Linking) VI - 45 DP - 2019 Aug TI - A multicenter study on the efficacy and safety of So-Cheong-Ryong-Tang for perennial allergic rhinitis. PG - 50-56 LID - S0965-2299(18)31228-7 [pii] LID - 10.1016/j.ctim.2019.05.018 [doi] AB - BACKGROUND: So-Cheong-Ryong-Tang (SCRT), also known as Xiao-Qing-Long-Tang or Sho-seiryo-to, is a mixed herbal formula that is used to treat allergic rhinitis, bronchitis, allergic asthma, and common cold in traditional Korean medicine. OBJECTIVE: To assess the efficacy and safety of the SCRT for the treatment of allergic rhinitis. METHODS: We conducted a double-blind, randomized, placebo-controlled, parallel-group, multicenter study of Korean adults with perennial allergic rhinitis. The trial consisted of a 4-week oral administration of SCRT or placebo, with two visits at 2-week intervals, and an 8-week follow-up period, with two visits at 4-week intervals. The primary outcome was a change in the total nasal symptoms score. The secondary outcomes included changes in the Rhinoconjunctivitis Quality of Life Questionnaire score, total serum immunoglobulin E (IgE), cytokines levels, and nasal endoscopy index. RESULTS: SCRT improved nasal symptoms and quality of life in patients with PAR after 4 weeks medication, and these effects did not last 8 weeks after the end of medication. The level of serum IgE, eosinophil counts, and cytokines did not alter after medication. Nasal endoscopy index did not show significant difference. No serious AEs and safety assessment changes were observed in this trial. CONCLUSION: SCRT is an effective and safe medication for patients with chronic, perennial, and moderate to severe AR. A clinical study with a >4-week period of medication use, and more participants for immune material test is needed to investigate the long-term efficacy of SCRT in relieving the symptoms of nasal obstruction and identifying the underlying mechanisms of action and indications for traditional Korean medicine. CI - Copyright (c) 2019 Elsevier Ltd. All rights reserved. FAU - Kim, Min Hee AU - Kim MH AD - Department of Ophthalmology, Otorhinolaryngology & Dermatology, College of Korean Medicine, Kyung Hee University, Seoul, Republic of Korea. Electronic address: mhkim@khnmc.or.kr. FAU - Hong, Seung-Ug AU - Hong SU AD - Department of Ophthalmology, Otorhinolaryngology & Dermatology, College of Korean Medicine, Dongguk University, Gyeongju, Republic of Korea. Electronic address: heenthsu@duih.org. FAU - Kim, Hee-Taek AU - Kim HT AD - Department of Ophthalmology, Otorhinolaryngology & Dermatology, College of Korean Medicine, Semyung University, Jecheon, Republic of Korea. Electronic address: kht8725c@semyung.ac.kr. FAU - Seo, Hyung-Sik AU - Seo HS AD - Department of Ophthalmology, Otorhinolaryngology & Dermatology, College of Korean Medicine, Pusan National University, Pusan, Republic of Korea. Electronic address: aran99@pusan.ac.kr. FAU - Kim, Kyuseok AU - Kim K AD - Department of Ophthalmology, Otorhinolaryngology & Dermatology, College of Korean Medicine, Kyung Hee University, Seoul, Republic of Korea. Electronic address: kmdkskim@khu.ac.kr. FAU - Ko, Seoung-Gyu AU - Ko SG AD - Department of Preventive Medicine, College of Korean Medicine, Kyung Hee University, Seoul, Republic of Korea. Electronic address: epiko@khu.ac.kr. FAU - Choi, Inhwa AU - Choi I AD - Department of Ophthalmology, Otorhinolaryngology & Dermatology, College of Korean Medicine, Kyung Hee University, Seoul, Republic of Korea. Electronic address: inhwajun@khnmc.or.kr. LA - eng PT - Clinical Trial PT - Journal Article PT - Multicenter Study PT - Randomized Controlled Trial DEP - 20190518 PL - Scotland TA - Complement Ther Med JT - Complementary therapies in medicine JID - 9308777 RN - 0 (Cytokines) RN - 0 (Drugs, Chinese Herbal) RN - 0 (sho-seiryu-to) SB - IM MH - Adult MH - Asthma/drug therapy/metabolism MH - Common Cold/drug therapy/metabolism MH - Cytokines/metabolism MH - Double-Blind Method MH - Drugs, Chinese Herbal/*adverse effects/*therapeutic use MH - Female MH - Humans MH - Male MH - Medicine, Korean Traditional/methods MH - Phytotherapy/methods MH - Quality of Life MH - Rhinitis, Allergic, Perennial/*drug therapy/metabolism MH - Treatment Outcome OTO - NOTNLM OT - Allergic rhinitis OT - Allergy OT - Herbal medicine OT - So-Cheong-Ryong-Tang OT - Xiao-Qing-Long-Tang EDAT- 2019/07/25 06:00 MHDA- 2020/01/10 06:00 CRDT- 2019/07/24 06:00 PHST- 2018/12/10 00:00 [received] PHST- 2019/03/15 00:00 [revised] PHST- 2019/05/13 00:00 [accepted] PHST- 2019/07/24 06:00 [entrez] PHST- 2019/07/25 06:00 [pubmed] PHST- 2020/01/10 06:00 [medline] AID - S0965-2299(18)31228-7 [pii] AID - 10.1016/j.ctim.2019.05.018 [doi] PST - ppublish SO - Complement Ther Med. 2019 Aug;45:50-56. doi: 10.1016/j.ctim.2019.05.018. Epub 2019 May 18.